Key Highlights
- FDA awarded priority review designation to two supplemental Biologics License Applications for KEYTRUDA and KEYTRUDA QLEX, both paired with Padcev.
- These submissions focus on muscle-invasive bladder cancer (MIBC) patients who qualify for cisplatin-based chemotherapy treatment.
- Regulatory decision deadline established for August 17, 2026.
- Phase 3 KEYNOTE-B15 clinical trial data demonstrating enhanced survival results forms the foundation for both submissions.
- Upon approval, this combination therapy would represent the inaugural perioperative option for MIBC patients irrespective of cisplatin suitability.
Merck has secured another promising opportunity for its leading oncology asset KEYTRUDA, with the FDA providing priority review designation for two bladder cancer treatment applications.
The pharmaceutical giant disclosed Monday that the FDA accepted two supplemental Biologics License Applications covering KEYTRUDA (pembrolizumab) and KEYTRUDA QLEX (pembrolizumab and berahyaluronidase alfa-pmph). Each application evaluates these therapies combined with Padcev (enfortumab vedotin-ejfv) for muscle-invasive bladder cancer patients eligible for cisplatin-based chemotherapy.
Under the Prescription Drug User Fee Act, the FDA established a target decision date of August 17, 2026.
Priority review designation applies to medications demonstrating potential for significant therapeutic advances in serious medical conditions. This classification generally compresses the evaluation period to approximately six months, versus the conventional ten-month timeline.
Clinical Trial Results
Both applications draw upon findings from the Phase 3 KEYNOTE-B15 clinical trial. This research demonstrated superior survival benefits for muscle-invasive bladder cancer patients receiving the KEYTRUDA-Padcev combination regimen.
While Merck withheld detailed trial metrics from Monday’s announcement, the FDA’s priority review authorization suggests the agency recognizes the data’s potential to transform treatment standards.
Presently, KEYTRUDA combined with Padcev holds approval for adult patients with locally advanced or metastatic urothelial cancer across the United States, European Union, Japan, and additional markets.
These new submissions aim to extend that indication into an earlier disease stage — the muscle-invasive phase — where therapeutic goals typically focus on cure rather than disease management.
Pioneering Treatment Classification
Upon regulatory clearance, the KEYTRUDA and KEYTRUDA QLEX combinations with Padcev would establish the first perioperative treatment options for MIBC patients without regard to cisplatin eligibility status.
This represents a significant advancement. The current approval covers MIBC patients unsuitable for cisplatin-based chemotherapy. These new applications would encompass cisplatin-eligible patients as well — substantially expanding the addressable patient population.
Perioperative therapy encompasses treatment administered before and after surgical intervention, which constitutes standard care for muscle-invasive bladder cancer. Entering this treatment paradigm with priority review status positions Merck favorably from a regulatory standpoint as the August decision deadline approaches.
KEYTRUDA QLEX represents a subcutaneous formulation of pembrolizumab, enabling administration through injection beneath the skin rather than intravenous infusion. This delivery method may provide practical advantages compared to traditional IV administration.
Merck’s shares advanced 3.13% Monday following the announcement. The August 17 target deadline now represents a critical milestone for investors monitoring the company’s oncology development pipeline.
